Daraxonrasib (Rasonque), the first-in-class RAS(ON) inhibitor that already transformed second-line metastatic pancreatic cancer treatment, is now pushing into the front line. The FDA granted breakthrough therapy designation to daraxonrasib combined with gemcitabine and nab-paclitaxel for treatment-naive metastatic pancreatic ductal adenocarcinoma (mPDAC), based on early but striking data from the phase 1/2 RMC-GI-102 trial.

In 40 previously untreated patients with RAS-mutant mPDAC, the combination produced a confirmed objective response rate of 58% — well above the 30–40% historically seen with standard first-line chemotherapy. Six-month progression-free and overall survival rates reached 84% and 90%, respectively, with median PFS and OS data still maturing. The safety profile was manageable and consistent with the known profiles of each agent. These results are now informing the design of the global phase 3 RASolute 303 trial, which will compare daraxonrasib monotherapy, daraxonrasib plus chemotherapy, and chemotherapy alone in the first-line setting.

By the Numbers:

• 58% confirmed objective response rate (vs. ~30–40% historical benchmark with chemo)
• 84% estimated 6-month progression-free survival rate
• 90% estimated 6-month overall survival rate
• 33% grade ≥3 anemia; 20% decreased neutrophil count; 18% fatigue — no grade 5 events
• Daraxonrasib was FDA-approved in August 2026 for previously treated mPDAC, where it doubled median OS (13.2 vs. 6.7 months) vs. chemotherapy

Why it matters: Daraxonrasib already rewrote the rules for second-line pancreatic cancer — one of oncology's most stubborn diseases. Moving it earlier, into the first-line setting, could extend its impact to a broader patient population and potentially reshape the entire treatment paradigm for a cancer where meaningful progress has been elusive for decades.